Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells

Molecular Cancer Research

Volumn 15, Issue 1, 2017, Pages 78-92

  Nakamura, Koji ^a   Sawada, Kenjiro ^a   Kinose, Yasuto ^a   Yoshimura, Akihiko ^a   Toda, Aska ^a   Nakatsuka, Erika ^a   Hashimoto, Kae ^a   Mabuchi, Seiji ^a   Morishige, Ken Ichirou ^b   Kurachi, Hirohisa ^c   Lengyel, Ernst ^d   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; MICRORNA; SMALL INTERFERING RNA; CD44 PROTEIN, HUMAN; MATRIX METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CELL COMMUNICATION; CELL INTERACTION; CELL INVASION; CELL TRANSFER; CELLULAR SECRETION; DOWN REGULATION; ELECTRON MICROSCOPY; EXOSOME; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MESOTHELIUM CELL; MOUSE; NONHUMAN; OVARY CANCER; PERITONEUM CELL; PHENOTYPE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; WESTERN BLOTTING; ZYMOGRAPHY; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL SHAPE; ENZYME INDUCTION; EPITHELIUM; EPITHELIUM CELL; METABOLISM; METASTASIS; NEOPLASM; NUDE MOUSE; OMENTUM; OVARY TUMOR; PATHOLOGY; PERITONEUM; SIGNAL TRANSDUCTION; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; ANTIGENS, CD44; CELL COMMUNICATION; CELL LINE, TUMOR; CELL SHAPE; DOWN-REGULATION; ENZYME INDUCTION; EPITHELIAL CELLS; EPITHELIUM; EXOSOMES; FEMALE; HUMANS; MATRIX METALLOPROTEINASES; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OMENTUM; OVARIAN NEOPLASMS; PERITONEUM; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 85009262010     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-16-0191     Document Type: Article

References (51)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30.
2. Kenny HA, Chiang CY, White EA, Schryver EM, Habis M, Romero IL, et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest 2014;124:4614-28.
3. Mutsaers SE. The mesothelial cell. Int J Biochem Cell Biol 2004;36:9-16.
4. Kenny HA, Nieman KM, Mitra AK, Lengyel E. The first line of intraabdominal metastatic attack: breaching the mesothelial cell layer. Cancer Discov 2011;1:100-2.
5. Davidowitz RA, Selfors LM, Iwanicki MP, Elias KM, Karst A, Piao H, et al. Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest 2014;124: 2611-25.
6. Iwanicki MP, Davidowitz RA, Ng MR, Besser A, Muranen T, Merritt M, et al. Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov 2011;1:144-57.
7. Lengyel E. Ovarian cancer development and metastasis. Am J Pathol 2010;177:1053-64.
8. Rieppi M, Vergani V, Gatto C, Zanetta G, Allavena P, Taraboletti G, et al. Mesothelial cells induce the motility of human ovarian carcinoma cells. Int J Cancer 1999;80:303-7.
9. Satoyoshi R, AibaN, Yanagihara K, Yashiro M, Tanaka M. Tks5 activation in mesothelial cells creates invasion front of peritoneal carcinomatosis. Oncogene 2015;34:3176-87.
10. Lee JK, Park SR, Jung BK, Jeon YK, Lee YS, KimMK, et al. Exosomes derived from mesenchymal stem cells suppress angiogenesis by down-regulating VEGF expression in breast cancer cells. PLoS One 2013;8:e84256.
11. Miyanishi M, Mandai M, Matsumura N, Yamaguchi K, Hamanishi J, Higuchi T, et al. Immortalized ovarian surface epithelial cells acquire tumorigenicity by Acrogranin gene overexpression. Oncol Rep 2007;17: 329-33.
12. Lasser C, Eldh M, Lotvall J. Isolation and Characterization of RNAContaining Exosomes. J Vis Exp 2012;59:e3037.
13. Kinose Y, Sawada K, Makino H, Ogura T, Mizuno T, Suzuki N, et al. IKKb regulates VEGF expression and is a potential therapeutic target for ovarian cancer as an antiangiogenic treatment. Mol Cancer Ther 2015; 14:909-19.
14. Kinose Y, Sawada K, Nakamura K, Sawada I, Toda A, Nakatsuka E, et al. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma. Oncotarget 2015;6:11342-56.
15. Sawada K, Morishige K, Tahara M, Kawagishi R, Ikebuchi Y, Tasaka K, et al. Alendronate inhibits lysophosphatidic acid-induced migration of human ovarian cancer cells by attenuating the activation of rho. Cancer Res 2002;62:6015-20.
16. Partridge J, Flaherty P. An in vitro FluoroBlok tumor invasion assay. J Vis Exp 2009;29:1475.
17. Lengyel E, Schmalfeldt B, Konik E, Spathe K, Harting K, Fenn A, et al. Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 2001; 82:291-8.
18. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T. Secretory mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem 2010;285:17442-52.
19. Kenny HA, Krausz T, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extracellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer 2007;121:1463-72.
20. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosomemediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9:654-9.
21. Zhang HG, Grizzle WE. Exosomes: a novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol 2014;184:28-41.
22. Grange C, Tapparo M, Collino F, Vitillo L, Damasco C, DeregibusMC, et al. Microvesicles released from human renal cancer stem cells stimulate angiogenesis and formation of lung premetastatic niche. Cancer Res 2011;71:5346-56.
23. Barberis MC, Faleri M, Veronese S, Casadio C, Viale G. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions. Acta Cytol 1997;41:1757-61.
24. Zigler M, Dobroff AS, Bar-Eli M. Cell adhesion: implication in tumor progression. Minerva Med 2010;101:149-62.
25. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol 2003;4:33-45.
26. Yu Q, Stamenkovic I. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 1999;13:35-48.
27. Tian T, Zhu YL, Zhou YY, Liang GF, Wang YY, Hu FH, et al. Exosome uptake through clathrin-mediated endocytosis and macropinocytosis and mediating miR-21 delivery. J Biol Chem 2014;289:22258-67.
28. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 2014;15:178-96.
29. Zoller M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule? Nat Rev Cancer 2011;11:254-67.
30. Sawada K, Radjabi AR, Shinomiya N, Kistner E, Kenny H, Becker AR, et al. c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. Cancer Res 2007;67:1670-9.
31. Lengyel E, Burdette JE, Kenny HA, Matei D, Pilrose J, Haluska P, et al. Epithelial ovarian cancer experimental models. Oncogene 2014;33: 3619-33.
32. Balaj L, Lessard R, Dai L, Cho YJ, Pomeroy SL, Breakefield XO, et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat Commun 2011;2:180.
33. Vaksman O, Trope C, Davidson B, Reich R. Exosome-derived miRNAs and ovarian carcinoma progression. Carcinogenesis 2014;35:2113-20.
34. Peinado H, Aleckovic M, Lavotshkin S, Matei I, Costa-Silva B, Moreno-Bueno G, et al. Melanomaexosomes educate bonemarrowprogenitor cells towarda pro-metastatic phenotype through MET. Nat Med 2012;18:883-91.
35. Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, et al. Cancersecreted miR-105 destroys vascular endothelial barriers to promotemetastasis. Cancer Cell 2014;25:501-15.
36. Singh A, Fedele C, Lu H, Nevalainen MT, Keen JH, Languino LR. Exosomemediated transfer of alphavbeta3 integrin from tumorigenic to nontumorigenic cells promotes a migratory phenotype. Mol Cancer Res. 2016 Jul. [Epub ahead of print].
37. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012;21: 309-22.
38. Sugiyama K, Kajiyama H, Shibata K, Yuan H, Kikkawa F, Senga T. Expression of the miR200 family of microRNAs in mesothelial cells suppresses the dissemination of ovarian cancer cells. Mol Cancer Ther 2014;13:2081-91.
39. Sawada K, Ohyagi-Hara C, Kimura T, Morishige K. Integrin inhibitors as a therapeutic agent for ovarian cancer. J Oncol 2012;2012:915140.
40. Ween MP, Oehler MK, Ricciardelli C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis. Int J Mol Sci 2011;12:1009-29.
41. Gardner MJ, Catterall JB, Jones LM, Turner GA. Human ovarian tumour cells can bind hyaluronic acid via membrane CD44: a possible step in peritoneal metastasis. Clin Exp Metastasis 1996;14:325-34.
42. Ryabtseva OD, Lukianova NY, Shmurakov YA, Polishchuk LZ, Antipova SV. Significance of adhesion molecules expression for estimation of serous ovarian cancer prognosis. Exp Oncol 2013;35:211-8.
43. Brown RL, Reinke LM, Damerow MS, Perez D, Chodosh LA, Yang J, et al. CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest 2011;121:1064-74.
44. Mima K, Okabe H, Ishimoto T, Hayashi H, Nakagawa S, Kuroki H, et al. CD44s regulates the TGF-b-mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res 2012;72:3414-23.
45. Cho SH, Park YS, Kim HJ, Kim CH, Lim SW, Huh JW, et al. CD44 enhances the epithelial-mesenchymal transition in association with colon cancer invasion. Int J Oncol 2012;41:211-8.
46. Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010;46:1271-7.
47. Kosaka N, Yoshioka Y, Tominaga N, Hagiwara K, Katsuda T, Ochiya T. Dark side of the exosome: the role of the exosome in cancer metastasis and targeting the exosome as a strategy for cancer therapy. Future Oncol 2014;10:671-81.
48. Ciravolo V, Huber V, Ghedini GC, Venturelli E, Bianchi F, Campiglio M, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy. J Cell Physiol 2012;227:658-67.
49. Aethlon Medical Inc. A medical device strategy to inhibit HER2+ breast cancer progression [updated 2011 Sep 27; cited 2015Oc 5]. Available from: http://www.aethlonmedical.com/assets/001/5080.pdf.
50. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013;4:2126.
51. Lobb RJ, Becker M, Wen SW, Wong CS, Wiegmans AP, Leimgruber A, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 2015;4:27031.